Swipe Left For English News
上海
2024年12月20日
全球领先的合同研究、开发和生产(CRDMO)服务公司药明生物(WuXi Biologics, 2269.HK)今日宣布和杭州多禧生物科技有限公司(“多禧生物” Hangzhou DAC Biotechnology Co., Ltd)与Aadi Bioscience(纳斯达克股票代码:AADI)达成研究服务合作协议,赋能Aadi公司研发三款处于临床前阶段的新一代抗体偶联药物(ADCs)。
此次合作的产品凝聚了药明生物和多禧生物的技术优势,应用了药明生物创新的抗体发现技术平台和多禧生物先进的有效载荷和连接子平台技术。根据协议条款,Aadi公司将向药明生物和多禧生物支付4400万美元首付款,最高达2.65亿美元的开发里程碑付款和5.4亿美元的商业里程碑付款,以及个位数比例的销售提成。
陈智胜博士
首席执行官
药明生物
我们很高兴通过先进的抗体发现服务加速赋能Aadi公司针对最具挑战性的癌症研发精准疗法。此次合作凸显了药明生物作为生物药发现服务领导者已获得广泛认可,并进一步验证了公司在新一代生物药领域为全球合作伙伴提供一体化发现技术平台的实力。我们期待与Aadi公司和多禧生物合作加速这些产品的开发和上市进程,造福全球患者。
David Lennon博士
总裁兼首席执行官
Aadi Bioscience
我们很高兴与药明生物和多禧生物达成合作,推进这些创新产品研发。在第一代ADC已经通过概念验证的背景下,我们审慎地选择了在肿瘤中广泛表达的靶点,并期望这些新一代ADC产品为癌症患者提供更出色的疗法。
赵永新博士
创始人兼首席执行官
多禧生物
我们非常荣幸能够与Aadi公司和药明生物达成这一具有战略意义的合作,Aadi公司在肿瘤精准治疗领域的深入理解和商业化能力,将为这些创新ADC项目的后续开发提供强有力的支持。未来,多禧生物将与药明生物继续扩大战略合作,持续赋能更多创新ADC候选分子。
关于药明生物
药明生物(股票代码:2269.HK)是一家全球领先的合同研究、开发和生产(CRDMO)公司。公司通过开放式、一体化生物制药能力和技术赋能平台,提供全方位的端到端服务,帮助合作伙伴发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队,以及先进技术和精深洞见,公司为客户提供高效经济的生物药解决方案。截至2024年6月底,药明生物帮助客户研发和生产的综合项目高达742个,其中包括16个商业化生产项目(不包括新冠项目和非活跃项目)。
药明生物将环境、社会和治理(ESG)视为业务发展和企业精神的重要组成部分,并致力于成为全球生物药CRDMO领域的ESG领导者,例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会,全面落实ESG战略并践行可持续性发展承诺。更多信息,请访问:www.wuxibiologics.com。
关于
Aadi Bioscience
Aadi是一家专注于肿瘤精准医疗的公司,致力于FYARRO®商业化,用于治疗局部晚期不可切除或转移性恶性血管周围上皮样细胞肿瘤(PEComa)成人患者。如需更多信息,请访问Aadi网站www.aadibio.com以及Twitter和LinkedIn。
关于
杭州多禧生物科技有限公司
杭州多禧生物科技有限公司成立于2012年,专注于抗体偶联(ADC)药物的研发、生产和商业化。经过10余年的研发沉淀,建立了具有自主知识产权的ADC药物技术平台,具备ADC药物从早期研发、工艺开发和商业化生产的全流程能力。
公司拥有30多项PCT国际专利申请,在主要发达国家专利申请数目超600项,仅在美国获得授权的专利达20余项。目前,公司产品管线丰富,覆盖世界上常见的大多数实体瘤种,拥有40余条处于不同研发阶段的ADC药物,已有6款药物处于临床试验阶段。
同时,公司凭借独有的技术平台优势,与美国强生等国内外多家知名药企都有密切而深入的合作。
业务垂询
info@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics and Hangzhou DAC Signed Research Service Agreement with Aadi Bioscience on Three Novel ADCs
Shanghai,
December 20, 2024
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it and Hangzhou DAC Biotechnology CO., LTD. (Hangzhou DAC) have signed a research service agreement with Aadi Bioscience, Inc. (NASDAQ: AADI) for a three-asset portfolio of preclinical next-wave antibody-drug conjugates (ADCs).
These assets were discovered through the collaborative efforts of WuXi Biologics and Hangzhou DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by Hangzhou DAC. Per the terms of the agreement, Aadi will pay WuXi Biologics and Hangzhou DAC upfront payments of $44 million for the three assets. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales.
Dr. Chris Chen
Chief Executive Officer
WuXi Biologics
Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers. This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and Hangzhou DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide.
Dr. David Lennon
President and CEO
Aadi Bioscience
I'm thrilled to announce our partnership with WuXi Biologics and Hangzhou DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer.
Dr. Robert Y. Zhao
President and CEO
Hangzhou DAC Biotechnology
We are thrilled to announce this strategic collaboration with Aadi and WuXi Bio. Aadi's in-depth knowledge of precision oncology and expertise in clinical development will provide robust support for future development of these three ADC programs. Meanwhile, we look forward to advancing our strategic collaboration with WuXi Bio and developing more innovative ADCs.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding 8 COVID CMO projects and 1 non-COVID dormant CMO project).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
About
Hangzhou DAC Biotechnology Co., Ltd.
Founded in 2012, Hangzhou DAC Biotechnology Co., Ltd. is a clinical stage biotech company, specializing in developing breakthrough ADC therapies. The company has established an end-to-end ADC drug development platform with the capacity of discovery, development and GMP production, and has built a rich product pipeline of over 40 ADC drugs, 6 of which are under clinical development.
Hangzhou DAC holds over 30 PCT patents and has filed over 600 patent applications worldwide. Leveraging its proprietary ADC platform, the company has established broad collaborations with multiple international pharmaceutical companies, including Johnson & Johnson.
About
Aadi Bioscience
Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
注:本信息不构成药明生物的信息披露或投资建议